surmount-1 trial tirzepatide weight loss non-diabetic SURMOUNT-1: Adults achieve of 16% or more at 72 weeks with Clinical trials of subcutaneous tirzepatide

These include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea and constipation Vomiting Abdominal pain or discomfort Dyspepsia (indigestion) These symptoms often improve as the body adjusts to the medication, which is why Saxenda is started at a low dose and gradually increased over five weeks

By mimicking this natural hormone, semaglutide works with your body's existing biology rather than against it

was supported by the National Institutes of Health (NIH

Science 370 , 856860 (2020)

Semaglutidea GLP-1 receptor agonist originally approved for type 2 diabeteshas become a cornerstone of weight loss treatment, with clinical trials showing 15% average body weight reduction over 68 weeks

In certain neurological conditions, iron buildup in particular tissues can also be seen